234 related articles for article (PubMed ID: 19584260)
21. Emerging targeted treatments for malignant glioma.
Mulholland PJ; Thirlwell C; Brock CS; Newlands ES
Expert Opin Emerg Drugs; 2005 Nov; 10(4):845-54. PubMed ID: 16262566
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis in malignant glioma--a target for antitumor therapy?
Tuettenberg J; Friedel C; Vajkoczy P
Crit Rev Oncol Hematol; 2006 Sep; 59(3):181-93. PubMed ID: 16860996
[TBL] [Abstract][Full Text] [Related]
23. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.
Yang W; Wu G; Barth RF; Swindall MR; Bandyopadhyaya AK; Tjarks W; Tordoff K; Moeschberger M; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
Clin Cancer Res; 2008 Feb; 14(3):883-91. PubMed ID: 18245552
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor as a target in cancer therapy.
Kim ES
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
[TBL] [Abstract][Full Text] [Related]
25. Cell surface receptors in malignant glioma.
Li YM; Hall WA
Neurosurgery; 2011 Oct; 69(4):980-94; discussion 994. PubMed ID: 21522029
[TBL] [Abstract][Full Text] [Related]
26. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
Hargrave D
Br J Neurosurg; 2009 Aug; 23(4):351-63. PubMed ID: 19637006
[TBL] [Abstract][Full Text] [Related]
27. Role of tyrosine kinase inhibitors in the management of high-grade gliomas.
Ahluwalia MS; Patel M; Peereboom DM
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1739-48. PubMed ID: 22050023
[TBL] [Abstract][Full Text] [Related]
28. Delivery systems and molecular targets of mechanism-based therapies for GBM.
Phuphanich S; Brat DJ; Olson JJ
Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
[TBL] [Abstract][Full Text] [Related]
29. Molecularly targeted therapy for malignant glioma.
Sathornsumetee S; Reardon DA; Desjardins A; Quinn JA; Vredenburgh JJ; Rich JN
Cancer; 2007 Jul; 110(1):13-24. PubMed ID: 17520692
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression.
Micallef J; Taccone M; Mukherjee J; Croul S; Busby J; Moran MF; Guha A
Cancer Res; 2009 Oct; 69(19):7548-56. PubMed ID: 19773446
[TBL] [Abstract][Full Text] [Related]
31. EGF receptor variant III as a target antigen for tumor immunotherapy.
Li G; Wong AJ
Expert Rev Vaccines; 2008 Sep; 7(7):977-85. PubMed ID: 18767947
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
33. Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies.
Argyriou AA; Antonacopoulou A; Iconomou G; Kalofonos HP
Crit Rev Oncol Hematol; 2009 Mar; 69(3):199-210. PubMed ID: 18602834
[TBL] [Abstract][Full Text] [Related]
34. Beyond grade: molecular pathology of malignant gliomas.
Sulman EP; Guerrero M; Aldape K
Semin Radiat Oncol; 2009 Jul; 19(3):142-9. PubMed ID: 19464628
[TBL] [Abstract][Full Text] [Related]
35. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
36. Nimotuzumab in pediatric glioma.
Lam C; Bouffet E; Bartels U
Future Oncol; 2009 Nov; 5(9):1349-61. PubMed ID: 19903064
[TBL] [Abstract][Full Text] [Related]
37. Clinical trials of small molecule inhibitors in high-grade glioma.
Day SE; Waziri A
Neurosurg Clin N Am; 2012 Jul; 23(3):407-16. PubMed ID: 22748653
[TBL] [Abstract][Full Text] [Related]
38. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
Argyriou AA; Giannopoulou E; Kalofonos HP
Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
[TBL] [Abstract][Full Text] [Related]
39. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
40. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]